Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months ... with ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... achieving returns of over 20% for the ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs ... Increasing US manufacturing of pharmaceuticals emerged as a more urgent priority during the Covid-19 pandemic as supply ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

Feb 20 (Reuters) - Eli Lilly (LLY.N), opens new tab is betting ... recent similar pre-launch inventory builds, especially around COVID-19 vaccines, but with the launch not coming until 2026 ...

(Reuters) - Eli Lilly is betting big on its experimental ... "There have been recent similar pre-launch inventory builds, especially around COVID-19 vaccines, but with the launch not coming ...